These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11035195)

  • 21. Assessment of high-affinity hybridization, RNase H cleavage, and covalent linkage in translation arrest by antisense oligonucleotides.
    Gee JE; Robbins I; van der Laan AC; van Boom JH; Colombier C; Leng M; Raible AM; Nelson JS; Lebleu B
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):103-11. PubMed ID: 9593048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is irrelevant cleavage the price of antisense efficacy?
    Stein CA
    Pharmacol Ther; 2000 Mar; 85(3):231-6. PubMed ID: 10739877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antisense phosphorothioate oligonucleotides direct both site-specific and nonspecific RNAse H cleavage of in vitro synthesized p120 mRNA.
    Weidner DA; Busch H
    Oncol Res; 1994; 6(6):237-42. PubMed ID: 7865899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Messenger RNA expression profiling of genes involved in epidermal growth factor receptor signalling in human cancer cells treated with scanning array-designed antisense oligonucleotides.
    Petch AK; Sohail M; Hughes MD; Benter I; Darling J; Southern EM; Akhtar S
    Biochem Pharmacol; 2003 Sep; 66(5):819-30. PubMed ID: 12948863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identifying Suitable Target Regions and Analyzing Off-Target Effects of Therapeutic Oligonucleotides.
    Pedersen L; Hagedorn PH; Koch T
    Methods Mol Biol; 2019; 2036():261-282. PubMed ID: 31410803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequence-specific RNase H cleavage of gag mRNA from HIV-1 infected cells by an antisense oligonucleotide in vitro.
    Veal GJ; Agrawal S; Byrn RA
    Nucleic Acids Res; 1998 Dec; 26(24):5670-5. PubMed ID: 9837998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antisense oligonucleotides: the state of the art.
    Aboul-Fadl T
    Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying accessible sites in RNA: the first step in designing antisense reagents.
    Pan WH; Clawson GA
    Curr Med Chem; 2006; 13(25):3083-103. PubMed ID: 17073649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting of antisense DNA: comparison of activity of anti-rabbit beta-globin oligodeoxyribonucleoside phosphorothioates with computer predictions of mRNA folding.
    Jaroszewski JW; Syi JL; Ghosh M; Ghosh K; Cohen JS
    Antisense Res Dev; 1993; 3(4):339-48. PubMed ID: 8155975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
    Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
    J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells.
    Giles RV; Spiller DG; Grzybowski J; Clark RE; Nicklin P; Tidd DM
    Nucleic Acids Res; 1998 Apr; 26(7):1567-75. PubMed ID: 9512525
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carba-LNA-5MeC/A/G/T modified oligos show nucleobase-specific modulation of 3'-exonuclease activity, thermodynamic stability, RNA selectivity, and RNase H elicitation: synthesis and biochemistry.
    Upadhayaya R; Deshpande SG; Li Q; Kardile RA; Sayyed AY; Kshirsagar EK; Salunke RV; Dixit SS; Zhou C; Földesi A; Chattopadhyaya J
    J Org Chem; 2011 Jun; 76(11):4408-31. PubMed ID: 21500818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oligonucleotide-based knockdown technologies: antisense versus RNA interference.
    Achenbach TV; Brunner B; Heermeier K
    Chembiochem; 2003 Oct; 4(10):928-35. PubMed ID: 14523910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The polypurine tract, PPT, of HIV as target for antisense and triple-helix-forming oligonucleotides.
    Volkmann S; Dannull J; Moelling K
    Biochimie; 1993; 75(1-2):71-8. PubMed ID: 7684936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RNase H sequence preferences influence antisense oligonucleotide efficiency.
    Kielpinski LJ; Hagedorn PH; Lindow M; Vinther J
    Nucleic Acids Res; 2017 Dec; 45(22):12932-12944. PubMed ID: 29126318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased efficacy of antileishmanial antisense phosphorothioate oligonucleotides in Leishmania amazonensis overexpressing ribonuclease H.
    Mishra M; Bennett JR; Chaudhuri G
    Biochem Pharmacol; 2001 Feb; 61(4):467-76. PubMed ID: 11226381
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fine-tuning of ENA gapmers as antisense oligonucleotides for sequence-specific inhibition.
    Takagi-Sato M; Tokuhiro S; Kawaida R; Koizumi M
    Oligonucleotides; 2007; 17(3):291-301. PubMed ID: 17854269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thermodynamic criteria for high hit rate antisense oligonucleotide design.
    Matveeva OV; Mathews DH; Tsodikov AD; Shabalina SA; Gesteland RF; Atkins JF; Freier SM
    Nucleic Acids Res; 2003 Sep; 31(17):4989-94. PubMed ID: 12930948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Artificial cationic oligosaccharides for heteroduplex oligonucleotide-type drugs.
    Hara RI; Hisada Y; Maeda Y; Yokota T; Wada T
    Sci Rep; 2018 Mar; 8(1):4323. PubMed ID: 29531343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of RNA secondary structure on cellular antisense activity.
    Vickers TA; Wyatt JR; Freier SM
    Nucleic Acids Res; 2000 Mar; 28(6):1340-7. PubMed ID: 10684928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.